Sponsor

Argenx

Belgium Industriepark-Zwijnaarde 7, 9052 Gent, Belgium

About the sponsor

Research activity centres on generalized myasthenia gravis, ocular myasthenia gravis, multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, amyotrophic lateral sclerosis, and congenital myasthenic syndromes, with additional interest in pediatric and adult forms of these conditions.

Myasthenia gravis
Chronic inflammatory demyelinating polyneuropathy
Amyotrophic lateral sclerosis

Trials also extend to AChR-antibody positive and seronegative disease subtypes, reflecting broad involvement across autoimmune neuromuscular weakness.

About Specializations

Argenx runs clinical trials in conditions such as Myasthenia gravis, Immune thrombocytopenia, Chronic inflammatory demyelinating polyradiculoneuropathy, Sjogren's syndrome, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

33 clinical trials

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Empasiprubart
Sponsor:Argenx

Contact Research Centre

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Myasthenia gravis

Recruiting

A Phase 2a Study of Empasiprubart IV Monotherapy in Adults with AChR‑Ab Seropositive Generalized Myasthenia Gravis

Registered drug

A Phase 2a Study of Empasiprubart IV Monotherapy in Adults with AChR‑Ab Seropositive Generalized Myasthenia Gravis

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Myasthenia gravis

Recruiting

A study to evaluate the safety and effectiveness of empasiprubart and efgartigimod alfa in patients with generalized myasthenia gravis.

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of empasiprubart and efgartigimod alfa in patients with generalized myasthenia gravis.

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

A study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy

Investigational

A study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Empasiprubart
Sponsor:Argenx

Contact Research Centre

Immune thrombocytopenia

Recruiting

Study of efgartigimod given by IV infusion in adolescents aged 12-17 years with chronic immune thrombocytopenia

Investigational

Study of efgartigimod given by IV infusion in adolescents aged 12-17 years with chronic immune thrombocytopenia

Investigational

France

Participants:0–17 years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Systemic scleroderma

Recruiting

Study on the Effectiveness and Safety of Efgartigimod PH20 SC for Adults with Systemic Sclerosis

Registered drug

Study on the Effectiveness and Safety of Efgartigimod PH20 SC for Adults with Systemic Sclerosis

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →

About the sponsor

About Specializations

Ongoing trials

33 clinical trials

Are you running a clinical trial?

Prefer not to search? Our Concierge searches the trials for you.